The University of Chicago Header Logo

Connection

Daniel Shevrin to Imidazoles

Back to Details
This is a "connection" page, showing publications Daniel Shevrin has written about Imidazoles.
Daniel Shevrin
Connection Strength
0.108
Imidazoles
  1. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44.
    View in: PubMed
    Score: 0.108
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.